ELSEVIER

Contraception 73 (2006) 654–656

Contraception

Author Index

Volume 73
January–June, 2006

Abbamonte, L.H., 537
Abdollahee, A., 554
Aguirre, A.C., 613
Akyuz, O., 88
Al-Aghbari, A., 301
Albertazzi, P., 577
Alessandri, F., 537
AL-Habori, M., 301
Allee, M.K., 408
Al-Mamary, M., 301
Almeida, J.A.M., 249
Alvarez, F., 46, 72, 364
Amaral, E., 542
Anderson, C., 265
Anderson, F.D., 229
Anserini, P., 537
Araujo, F.F., 361
Araújo, F.F., 594
Archer, D.F., 59
Athayde, C., 249
Austin, G., 588

Bacon, L., 111
Bahamondes, L., 97, 532, 634
Bajos, N., 602
Ballagh, S.A., 59
Baracat, E.C., 30, 361
Barberis, L., 78
Barbieri, M., 361, 594
Barbosa, I.C., 30
Barfield, J.P., 6
Bateman, L.H., 440
Bates, G.W. Jr., 512
Beksinska, M., 386, 394
Bellamy, S., 613
Benjawang, W., 356
Bennett, I., 613
Bera, S., 284
Berenson, A.B., 274
Birtch, R.L., 235
Bissell, P., 265
Bjørge, L., 109
Blough, D.K., 501
Borgatta, L., 415, 525
Bortolotti de Mello Jacobucci, M.S., 594
Bottazzi, M., 577
Bozkaya, H., 311
Brache, V., 46, 72, 364
Brandenburg, U., 493
Breitkopf, C.R., 274
Bretelle, F., 244
Brindis, C., 211
Brown, A., 408
Buckley, T., 41

Cabral, Z.A.F., 249
Cagnacci, A., 348
Caliskan, E., 88
Callahan, M.M., 59
Carletta, A., 53
Cavenague, G., 344
Chen, A.Y., 415
Choi, J., 623
Chrisman, C.E., 115, 125
Chuang, C.H., 382
Cochon, L., 46, 72
Coffey, P.S., 588
Cohen, J., 588
Cohen, J.A., 72
Comp, P.C., 4
Condon, S., 399
Cooper, T.G., 6
Coutinho, E.M., 249
Creinin, M.D., 59, 440, 618
Croxatto, H., 108
Croxatto, H.B., 46
Cullins, V., 420
Cullins, V.E., 440
Curtis, K.M., 113, 115, 125, 134, 145, 154, 166, 179, 189, 195, 205, 445, 470
Cwiak, C.A., 609

da Silva, B.L., 249
Daniele, M.B., 78
d'Arcangues, C., 443
Darney, P.D., 557
Davis, A.R., 488
De Angelo Andrade, L.A., 634
de Lima, G.R., 361
de Melo, N.R., 249
Dede, F.S., 88
Dhar, J.D., 102
Dieben, T., 368
Dilbaz, B., 88
Dilbaz, S., 88
Doyle, L.L., 440
Dunselman, G., 257
Dwivedi, A.K., 102

Eastwood, K., 53
Edelman, A.B., 609
Elliott, A.M., 331
Ellis, S.C., 525
El-Refaey, H., 261
Emmons, S.L., 609
Endrikat, J., 336
Espejo-Arce, X., 532

Faggion, D. Jr., 30
Faundes, A., 46, 97, 364, 542
Ferreira, C., 433
Ferrero, S., 537
Filho, C.I., 30
Findley-Klein, C., 65
Fleischman, J., 613

0010-7824/$ – see front matter
doi:10.1016/S0010-7824(06)00148-X

ELSEVIER

Contraception 73 (2006) 654–656

Contraception

Author Index

Volume 73
January–June, 2006

Abbamonte, L.H., 537
Abdollahee, A., 554
Aguirre, A.C., 613
Akyuz, O., 88
Al-Aghbari, A., 301
Albertazzi, P., 577
Alessandri, F., 537
AL-Habori, M., 301
Allee, M.K., 408
Al-Mamary, M., 301
Almeida, J.A.M., 249
Alvarez, F., 46, 72, 364
Amaral, E., 542
Anderson, C., 265
Anderson, F.D., 229
Anserini, P., 537
Araujo, F.F., 361
Araújo, F.F., 594
Archer, D.F., 59
Athayde, C., 249
Austin, G., 588

Bacon, L., 111
Bahamondes, L., 97, 532, 634
Bajos, N., 602
Ballagh, S.A., 59
Baracat, E.C., 30, 361
Barberis, L., 78
Barbieri, M., 361, 594
Barbosa, I.C., 30
Barfield, J.P., 6
Bateman, L.H., 440
Bates, G.W. Jr., 512
Beksinska, M., 386, 394
Bellamy, S., 613
Benjawang, W., 356
Bennett, I., 613
Bera, S., 284
Berenson, A.B., 274
Birtch, R.L., 235
Bissell, P., 265
Bjørge, L., 109
Blough, D.K., 501
Borgatta, L., 415, 525
Bortolotti de Mello Jacobucci, M.S., 594
Bottazzi, M., 577
Bozkaya, H., 311
Brache, V., 46, 72, 364
Brandenburg, U., 493
Breitkopf, C.R., 274
Bretelle, F., 244
Brindis, C., 211
Brown, A., 408
Buckley, T., 41

Cabral, Z.A.F., 249
Cagnacci, A., 348
Caliskan, E., 88
Callahan, M.M., 59
Carletta, A., 53
Cavenague, G., 344
Chen, A.Y., 415
Choi, J., 623
Chrisman, C.E., 115, 125
Chuang, C.H., 382
Cochon, L., 46, 72
Coffey, P.S., 588
Cohen, J., 588
Cohen, J.A., 72
Comp, P.C., 4
Condon, S., 399
Cooper, T.G., 6
Coutinho, E.M., 249
Creinin, M.D., 59, 440, 618
Croxatto, H., 108
Croxatto, H.B., 46
Cullins, V., 420
Cullins, V.E., 440
Curtis, K.M., 113, 115, 125, 134, 145, 154, 166, 179, 189, 195, 205, 445, 470
Cwiak, C.A., 609

da Silva, B.L., 249
Daniele, M.B., 78
d'Arcangues, C., 443
Darney, P.D., 557
Davis, A.R., 488
De Angelo Andrade, L.A., 634
de Lima, G.R., 361
de Melo, N.R., 249
Dede, F.S., 88
Dhar, J.D., 102
Dieben, T., 368
Dilbaz, B., 88
Dilbaz, S., 88
Doyle, L.L., 440
Dunselman, G., 257
Dwivedi, A.K., 102

Eastwood, K., 53
Edelman, A.B., 609
Elliott, A.M., 331
Ellis, S.C., 525
El-Refaey, H., 261
Emmons, S.L., 609
Endrikat, J., 336
Espejo-Arce, X., 532

Faggion, D. Jr., 30
Faundes, A., 46, 97, 364, 542
Ferreira, C., 433
Ferrero, S., 537
Filho, C.I., 30
Findley-Klein, C., 65
Fleischman, J., 613

0010-7824/$ – see front matter
doi:10.1016/S0010-7824(06)00148-X

Foidart, J.-M., 34
Forcelledo, M., 46
Foster, A.M., 408
Fowler, D., 271
Fu, N., 271

Gabriel, H., 325
Gadea, A., 628
Gaffield, M.E., 125, 134
Gamerre, M., 244
Garcia, A.-G., 364
Gardner, J., 372, 501
Gatter, M., 420
Geater, A., 356
Gentile, G.P., 507
Gerlinger, C., 336
Ghavami, S., 56
Ghosh, D., 284
Gibbons, W., 229
Gilliam, M., 404
Giordano, M., 537
Glasier, A., 1, 520
Glasier, A.F., 445
Gmach, R., 628
Godfrey, E., 440
Goh, S.E., 516
Goldberg, A., 376
Grey, T., 628
Grossman, M.P., 562
Guazzelli, C.A., 361
Guazzelli, C.A.F., 594
Guidicelli, B., 244
Gunes, M., 528
Gupta, G., 102

Haberal, A., 528
Hadas, E., 641
Halperin, R., 641
Hannaford, P.C., 331
Harrison-Woolrych, M., 111
Hartmann, K., 399
Harwood, B.J., 618
Hashemi, M., 56
Hausknecht, R., 109
Hays, M., 376
Heckenroth, H., 244
Heithecker, R., 336
Helbig, D.W., 507
Henderson, A., 623
Henry, D.M., 59
Hidalgo, M.M., 532, 634
Hoffman, M., 598
Hubacher, D., 628
Huber, J., 23

Ishiyama, V., 307
Iversen, O.E., 109Jana, D., 284

Jana, K., 289
Jarquin, C., 628
Jick, H., 223, 566
Jick, S.S., 223, 566
Joanis, C., 386
Jordan, B., 437
José Munuce, M., 97
Juliato, C.T., 532
Junmin, J., 92

Kalaichelvan, V., 352
Kapp, N., 525
Kassem, A., 301
Kaye, J.A., 223, 566
Kayikcioglu, F., 528
Kazerooni, T., 554
Kelekci, S., 279
Khan, I.M., 609
Kilbourne-Brook, M., 588
Kluft, C., 336
Krisanapan, O., 356
Kronfeld-Schor, N., 641
Kuehl, T.J., 41
Kurtaran, V., 88

Lamvu, G., 399
Lawton, B.A., 431
Lee, Y.J., 507
Legardy, J.K., 195
Levine, J.P., 613
Liekens, G., 493
Lifeng, T., 92
Lindsey, P.C., 361
Lippes, J., 433
Lisondo, C., 532
Liu, Y., 548
Longsheng, C., 92
Luukkainen, T., 110

Mabude, Z., 386, 394
Machado, R.B., 344
Magalhaes, D., 433
Maia, E., 344
Maiti, R., 284
Malaviya, B., 645
Martins, S.L., 154, 166, 179, 445, 470
Massai, R., 46
Mauck, C., 542
Mauck, C.K., 59
Maw, A.A., 352
Mazouni, C., 244
McNulty, J., 65
Medrano, J., 628
Memmel, L.M., 372
Mikolajczyk, R.T., 107

Miller, L., 372, 501
Mina, M., 111
Mitchel, H., 261
Mohllajee, A.P., 115, 125, 134, 145, 154, 166, 179, 189, 205
Mokhtari, M., 56
Momtaz, M.R., 420
Monteiro, I., 532
Moreau, C., 602
Morfesis, J., 420
Moron, A.F., 594
Morroni, C., 598
Mosekilde, L., 571
Moseman, C.P., 512
Moss, M., 598
Mottl-Santiago, J., 415
Mousavizadeh, K., 554
Mulder, S.M., 336
Murphy, P., 440
Myer, L., 598

Naderi, M., 56
Nakajima, S.T., 562
Nappi, R.E., 493
Nascimento, J.A., 97
Nathirojanakun, P., 584
Ness, R.B., 618
Neto, J.S.P., 249
Newman, J., 274
Nieschlag, E., 6
Noronha, C.F., 249

Ojha, P., 102
Okumuş, B., 311
Olatunbosun, O.A., 235
Oliveira-Ribeiro, M., 634
Orihuela, P.A., 307
Osborne, L.M., 488
Osmanağaoğlu, M.A., 311
Ozdegirmenci, O., 528
Ozturk, O., 261

Pájaro, C., 78
Paoletti, A.M., 348
Park, T., 507
Pascual, L.M., 78
Patel, A., 420
Paul, D., 284
Pavez, M., 46
Pellogia, A., 634
Pelta, M., 420
Perdigao, A., 542
Peterson, H.B., 113, 115, 125, 134, 145, 154, 166, 179, 189, 205
Petta, C.A., 634
Phupong, V., 253

Picardo, C., 559
Pierre-Louis, B., 628
Pierson, R.A., 235
Pinjaroen, S., 356
Piotrowski, H., 420
Polis, C., 408
Porcu, G., 244
Portman, D., 229
Praisuwanna, P., 368
Pretorius, E.S., 82
Propst, A.M., 512
Provensal, M., 244
Pymar, H.C., 59

Qianli, W., 92

Ragni, N., 537
Rahimi, M., 56
Ralph, L., 211
Rashidi, H., 56
Raymond, E.G., 376
Reeves, M.F., 618
Reinprayoon, D., 368
Rejnmark, L., 571
Remorgida, V., 537
Renzi, A., 348
Roach, E., 376
Robinson, J., 65
Robinson, R.D., 512
Rodeck, C., 261
Rodriguez, P., 440
Rosano, G., 97
Rose, S.B., 431
Rumi, D.O., 249
Russmann, S., 223, 566

Salemans, T., 257
Salvatierra, A.M., 46
Samanta, P.K., 289
Sappakitkumjorn, N., 584
Sarkarian, M., 554
Sattar, A., 554
Savage, I., 265
Savan, K., 279
Schafer, J.E., 488
Schellschmidt, I., 34
Schreiber, C.A., 618
Schünmann, C., 520
Schwartz, J.L., 59
Seamans, Y., 588
Severy, L.J., 65
Shabbout, M., 82
Shah, I.H., 548
Shank, L.D., 382
Sharma, S., 261
Shaunik, A., 82
Shepherd, J., 431
Shera, D.M., 82
Shields, W.C., 1, 211, 557
Shinnar, N., 641
Shotorbani, S., 501
Shoulin, W., 92
Shulman, L.P., 319, 325, 440
Simmonds, K., 408
Singh, K., 352
Singh, N., 645
Singh, R.L., 102
Sitruk-Ware, R., 215
Sivin, I., 315
Smit, J., 386, 394
Sonmez, S., 279
Soonthornpun, K., 356
Sophonsritsuk, A., 253
Sorensen, E.C.H., 109
Souza, M.H., 542
Spear, S.J., 440
Spinola, P., 249
Stanford, J.B., 107
Stanwood, N.L., 53
Steel, S.A., 577
Steiner, M.J., 399
Stewart, F.H., 440
Stubblefield, P., 525
Sulak, P.J., 34, 41
Switzer, G.E., 618

T. Barnhart, K., 82
Tachotti, F., 344
Taheri, M., 56
Talmont, E., 420
Taneepanichskul, S., 253, 368, 584
Taylor, D., 376
Thaithumyanon, P., 368
the Planned Parenthood Federation of America Buccal Misoprostol Waiver Group, 420
The Yasmin® Extended Regimen Study Group, 34
Thomas, M.A., 440
Thong, K.J., 516
Tirelli, A., 348
Tosukhowong, P., 368
Trouton, K., 271, 623
Trussell, J., 376, 437, 602

van Grootheest, A., 257
Van Houdenhoven, K., 257
van Kaam, K., 257
Vestergaard, P., 571
Vigorito, N.M., 361
Vijayakumar, G., 386, 394
Vilchez, R., 628
Vogelsong, K.M., 548
Volpe, A., 348
Vragovic, O., 415

Walch, K., 23
Waller, D., 542
Wasserman, S., 415
Weiner, D.H., 59
Westhoff, C., 488
Westhoff, C.L., 440, 507
Wiebe, E., 271
Wiebe, E.R., 623
Wildemeersch, D., 110, 316
Worthington, S., 440
Wu, J.P., 613
Wu, Z.H., 274
Wuellner, S., 404

Xuezhao, S., 92

Yakut, Y., 279
Yannan, L., 92
Yasar, L., 279
Yilmaz, B., 279

Zacur, H., 507
Zaneveld, L., 542
Zhang, L., 548
Zimmermann, D., 34
Zite, N., 404
Zurek, M., 408

ELSEVIER

Contraception 73 (2006) 657–667

Contraception

Subject Index

Volume 73
January–June, 2006

Abortion,
in adolescents, mandating parental involvement, ARHP editorial, 211
effect of *Prangos ferulacia* as agent for (rat), 554
at more than 15 weeks' gestation, in patients with previous cesarean section, 244
second-trimester, safety and adequacy of buccal misoprostol for cervical preparation before, 420
Abortion education,
among family medicine residents, effect of educational intervention on interest in, 613
in NP, PA and CNM programs in the United States, 408
Acceptability,
EE + DRSP (Yasmin®) in an extended 126-day regimen, 34
FemCap™ with removal strap, 59
GTD + EE (Minesse®), 30
home monitor used to aid in conception, 65
once-a-month injectable testosterone undecanoate as male contraceptive in China, 548
short-term, of PATH Woman's Condom among users in Mexico, South Africa and Thailand, 588
transition from Norplant to Jadelle, 364
vaginal ring vs OC using Quick Start initiation, 488
Achyranthes aspera, and *Stephania hernandifolia*, extract, in vitro effect on spermicidal viability, 284
ACIDFORM, vs 2% nonoxynol-9 microbicide, vaginal safety of, 542
Acne, treatment with lower doses of OC, review, 23
Acrosome reaction, of human spermatozoa, in vitro effect of LNG doses comparable to that delivered by LNG-IUS, 97
Actinomyces israelii, in cervical smears of Singaporean women using IUD, 352
Adolescents,
female, relation of sexual behavior to source of sexual information among, 274
mandating parental involvement in abortion of, ARHP editorial, 211
users of injectable NET-EN + estradiol valerate, bleeding patterns among, 594
Age, at female sterilization, association with poststerilization regret, review, 205
Age factors, in use of new T-shaped LNG-IUS, 110
Alanine transaminase (ALT), effects of Norplant in Iranian women, 56
ALT (alanine transaminase)
Angioedema, acquired, and Factor V Leiden mutation, skin VTE by COC in women with, 311
Antifertility effect, potential, of fenugreek seeds in female and male (rabbit), 301
Antispermatogenic agents, effect on cell marker enzymes of Sertoli cells in vitro (rat), 102
ARHP (Association of Reproductive Health Professionals)
Aromatase, effect of antispermatogenic agents in Sertoli cells in vitro (rat), 102
Aspartate transaminase (AST), effects of Norplant in Iranian women, 56
Association of Reproductive Health Professionals (ARHP) editorial,
can we improve contraceptive use?, 1
mandating parental involvement in adolescents' abortion, 211
reproductive health risks in perspective, 437
the society of family planning, 557
World Health Organization's global guidance for family planning, 113
AST (aspartate transaminase)
Attitudes,
about contraception among primary care medical students, 618
of health care providers in US regarding extended-cycle OC, 41
on home monitor used to aid in conception, 65
on IUD, impact of medical education, randomized trial, 628
of women, about the vagina, International Vagina Dialogue Survey, 493

Barrier contraceptive, FemCap™ with removable strap, ease of removal, safety and acceptability, 59
Bioelectric impedance analysis, effects of EE + GTD vs EE + DRSP on total body water, 344

0010-7824/S – see front matter
doi:10.1016/S0010-7824(06)00149-1

Bipolar electrocautery,
of fallopian tubes for voluntary surgical contraception, effect on menstrual pattern and ovarian function, 88
vs Hulka clip sterilization, hormone levels before and after, 507
Bleeding pattern,
after TOP using two dosing schedules of mifepristone + misoprostol, 415
after use of LNG EC pills, 376
among adolescent users of injectable NET-EN + estradiol valerate, 594
effect of GTD + EE (Minesse®), 30
effects of EE + DRSP (Yasmin®) in an extended 126-day regimen, 34
effects of smoking, review, 562
Blood pressure, effects of LNG-IUS, 528
BMD (bone mineral density)
Bone health,
effects of combined hormonal contraception, review, 445
effects of progestogen-only contraception, review, 470
and hormonal contraception, WHO statement, 443
Bone mineral density (BMD),
effects of switching from DMPA to OC pill, 577
and fracture risk
effects of combined hormonal contraception, review, 445
effects of progestogen-only contraception, review, 470
Breakthrough bleeding,
effects of smoking, review, 562
endometrial histology, microvascular density and MMP-3 expression in users of Nestorone®-releasing contraceptive implants with and without, 634
Breast-feeding, infants, effects of nonmedicated IUD vs Implanon® on growth of, 368
Bromhexine, effects on glycoprotein expression in uterus in trophectoderm (rat), 645
Buccal administration, of misoprostol, adequacy and safety for cervical preparation before second-trimester TOP, 420

Calcium chloride, single intratesticular injection for nonsurgical sterilization (rat), 289
Casein, intrauterine injection, effect on fetal survival (rat), 641
CDRI-84/35, effect on cell marker enzymes of Sertoli cells in vitro (rat), 102
Certified nurse-midwifery (CNM), programs in the United States, abortion education in, 408
Cervical preparation, before second-trimester TOP, safety and adequacy of buccal misoprostol for, 420
Cervical smears, of Singaporean women using IUD, *Actinomyces israelii* in, 352
Cesarean section, previous, TOP at more than 15 weeks' gestation in patients with, 244
China, acceptability of once-a-month injectable testosterone undecanoate as male contraceptive in, 548
Cholesterol, total, effects of Norplant in Iranian women, 56
Cigarette smoking, effects on bleeding patterns, review, 562
CNM (certified nurse-midwifery)
Coagulation tests, to determine risk of thrombophlebitis in OC users, 4
COC (combined oral contraceptive)
Colposcopy, clinical safety of three vaginal applicators, 72
Combined hormonal injectables, effective use, review, 125
Combined hormonal patch, medical eligibility criteria for, review, 134
Combined hormonal vaginal ring, medical eligibility criteria for, review, 134
Combined oral contraceptive (COC),
causing skin VTE in women with acquired angioedema and Factor V Leiden mutation, 311
EE + DRSP
vs DSG + EE, effects on hemostasis, 336
vs EE + GTD, effects on total body water, 344
EE + DSG vs EE + CPA, in women with polycystic ovary syndrome, effects on Hcy metabolism, 348
effective use, review, 115
use among women
with hypertension, review, 179
with migraine vs nonmigrainous headaches, review, 189
with thrombogenic mutations, effect on risk of venous thromboembolism, review, 166
use of lower doses in acne treatment, review, 23
Community pharmacies, pharmacists' perspectives on supply of emergency hormonal contraception via patient group direction in UK, 265
Condom, female,
PATH Woman's Condom, short-term acceptability among users in Mexico, South Africa and Thailand, 588
Reality® vs synthetic latex prototype
performance among South African women, 386
short-term acceptability among South African women, 394
Continuation rate, of Norplant implantation in southern Thai women, 356
Contraception,
attitudes and knowledge among primary care medical residents, 618
curriculum, impact on knowledge retention and learning skills of medical students, 609
effect of postcoital ingestion of aqueous extract of *Erythrina falcata* Benth (mouse), 307
influence of health care providers in consistency between current method used and reasons for use of, 399
international perspective, review, 215
perceptions of ethnic Korean women about, 623
progestogen-only, effects on fracture risk and BMD, review, 470
Contraceptive counseling, new recommendations for the periodic well-woman visit, 319
Contraceptive implants,
acceptability of Norplant transition to Jadelle, 364
effective use, review, 125
Implanon® vs Jadelle®, ovarian cysts in users of, 532

Contraceptive implants, (*continued*)
Nestorone®-releasing, endometrial histology, microvascular density and MMP-3 expression in users with and without endometrial bleeding, 634
Contraceptive use,
for family planning, World Health Organization's guidelines, ARHP editorial, 113
in France, impact of pharmacy access to EC pills on, 602
improvement, ARHP editorial, 1
and unintended pregnancy, among women who undergo induced abortion, 520
Copper intrauterine device (IUD), insertion and use, effect on risk of PID among women with STI, review, 145
Counseling, new recommendations for the periodic well-woman visit, 319
Couple relationships, psychological acceptability of home monitor used to aid in conception, 65
CPA (cyproterone acetate)
Curriculum,
abortion education in NP, PA and CNM programs in the United States, 408
on contraception, impact on knowledge retention and learning skills of medical students, 609
Cyproterone acetate (CPA) + EE, vs DSG + EE, in women with polycystic ovary syndrome, effects on Hcy metabolism, 348

Decision making, evidence-based, about product labeling, by FDA, 440
Depo-Provera (depot-medroxyprogesterone acetate)
Depot-medroxyprogesterone acetate (DMPA),
can we improve contraceptive use?, ARHP editorial, 1
efficacy of valdecoxib for controlling irregular uterine bleeding in users of, 584
vs NET-EN, injectable, preferences among South African women, 598
pharmacist-administered, 559
switch to OC pill, effects on BMD, 577
Desogestrel (DSG), or norgestimate, vs LNG, risk of nonfatal VTE with, 566
Desogestrel (DSG) + EE,
vs EE + CPA, in women with polycystic ovary syndrome, effects on Hcy metabolism, 348
vs EE + DRSP, effects on hemostasis, 336
Dihydroxyprogesterone acetophenide + estradiol enanthate, monthly injectable contraceptive, comparison of two regimens, 249
Discontinuation rate, cumulative gross, of IUD, 315
DMPA (depot-medroxyprogesterone acetate)
Doppler analysis, effects of laparoscopic tubal sterilization on hormonal and ovarian stromal blood supply, 279
Drospirenone (DRSP) + EE,
vs DSG + EE, effects on hemostasis, 336
vs GTD + EE, effects on total body water, 344
Yasmin®, safety, acceptance and bleeding profile in an extended 126-day regimen, 34
DRSP (drospirenone)
Drug dose,
of LNG comparable to that delivered by LNG-IUS, effect on in vitro expression of zona binding sites of human spermatozoa, 97
mifepristone + misoprostol, bleeding patterns after using two dosing schedules for TOP, 415
DSG (desogestrel)

EC (emergency contraception)
Educational intervention, effect on interest in early abortion training among family medicine residents, 613
EE (ethinyl estradiol)
Efficacy,
mifepristone + misoprostol
for TOP at more than 15 weeks' gestation in patients with previous cesarean section, 244
vaginal, in early medical abortion, 261
Seasonique™, 229
valdecoxib for controlling irregular uterine bleeding in DMPA users, 584
Emergency contraception (EC),
availability at rural and urban pharmacies in Pennsylvania, 382
can we improve contraceptive use, ARHP editorial, 1
LNG, effects on ovulatory dysfunction, 107
Nestorone® + EE vaginal ring for, 46
Emergency contraception (EC) pills,
bleeding patterns after use of LNG, 376
pharmacy access to, impact on contraceptive use and sexual behavior in France, 602
Emergency hormonal contraception, supply via patient group direction in UK, pharmacists' perspectives, 265
Endometrial bleeding, in users of Nestorone®-releasing contraceptive implants with and without, 634
Endometrial safety, of EE + DRSP (Yasmin®) in an extended 126-day regimen, 34
Erythrina falcata Benth, aqueous extract, contraceptive effect of postcoital ingestion (mouse), 307
Estradiol, levels before and after bipolar electrocautery vs Hulka clip sterilization, 507
Estradiol enanthate + dihydroxyprogesterone acetophenide, monthly injectable contraceptive, comparison of two regimens, 249
Estradiol valerate + NET-EN, injectable, bleeding patterns among adolescent users, 594
Ethinyl estradiol (EE), continuous low-dose, safety and efficacy of extended-regimen OC utilizing, 229
Ethinyl estradiol (EE) + DRSP,
vs DSG + EE, effects on hemostasis, 336
Yasmin®, safety, acceptance and bleeding profile in an extended 126-day regimen, 34
Ethinyl estradiol (EE) + DSG, vs EE + CPA, in women with polycystic ovary syndrome, effects on Hcy metabolism, 348

Ethinyl estradiol (EE) + GTD,
vs EE + DRSP, effects on total body water, 344
Minesse®, safety and acceptability, 30
Ethinyl estradiol (EE) + Nestorone®, vaginal ring for EC, 46
Ethinyl estradiol (EE) + norgestimate, OC vs transdermal patch, risk of nonfatal VTE in women using, 223
Ethnic Korean women, perceptions about contraception, 623
Etonogestrel implant, medical eligibility criteria for, review, 134
Evidence-based decision making, about product labeling, by FDA, 440
Evidence-based guidelines, for family planning, by WHO, ARHP editorial, 113
Exogenous hormones, effects on lung cancer risk in women, 331
Extended cycle OC,
over 126 days, bleeding profile, safety and acceptance of EE + DRSP (Yasmin®), 34
attitudes and prescribing patterns of health care providers in US regarding use of, 41
utilizing continuous low-dose EE, safety and efficacy, 229

Factor V Leiden mutation,
and acquired angioedema, skin VTE by COC in women with, 311
effect of hormonal contraceptive use on risk of venous thromboembolism among women with, review, 166
Fallopian tubes, bipolar electrocautery for voluntary surgical contraception, effect on menstrual pattern and ovarian function, 88
Family medicine residents, effect of educational intervention on interest in early abortion training among, 613
Family planning, World Health Organization's global guidance, ARHP editorial, 113
FDA (United States Food and Drug Administration)
Female condom,
PATH Woman's Condom, short-term acceptability among users in Mexico, South Africa and Thailand, 588
Reality® vs synthetic latex prototype
performance among South African women, 386
short-term acceptability among South African women, 394
Female sterilization,
with quinacrine, decreased failures due to transvaginal sonographic diagnosis of septate uteri, 433
at young age, association with poststerilization regret, review, 205
FemCap™, with removal strap, ease of removal, safety and acceptability, 59
Fenugreek seed, evaluation of potential antifertility effect in female and male (rabbit), 301
Fenvalerate, effects on semen quality among occupational workers exposed to, 92
Fertility, effect of single intratesticular injection of calcium chloride (rat), 289
Fertility control, in wildlife, humans as models, 6
Fetal malformations, and termination of twin pregnancy failure, 109
Fetal survival, effect of intrauterine casein injection on (rat), 641
Follicular development, during conventional vs continuous OC use, 235
Fracture risk,
and BMD
effects of combined hormonal contraception, review, 445
effects of progestogen-only contraception, review, 470
and OC, 571
France, impact of pharmacy access to EC pills on contraceptive use and sexual behavior in, 602
Friends, as source of sexual information, relation to sexual behavior among female adolescents, 274

Gestodene (GTD) + EE,
vs EE + DRSP, effects on total body water, 344
Minesse®, safety and acceptability, 30
Glucose metabolism, effects of LNG-IUS, 528
Γ-Glutamyl transpeptidase, effect of antispermatogenic agents in Sertoli cells in vitro (rat), 102
Glycoproteins, expression in uterus in trophectoderm, effects of bromhexine on (rat), 645
Gossypol, effect on cell marker enzymes of Sertoli cells in vitro (rat), 102
GTD (gestodene)

H_2O_2 (hydrogen peroxide)
Hcy (homocysteine)
Headache, nonmigrainous vs migraine, risk of stroke among COC users with, review, 189
Health care providers,
attitudes and prescribing patterns regarding extended-cycle OC in US, 41
influence in consistency between reasons for initiating contraception and current method used, 399
vs women, agreement on risk assessment of hormonal contraception, 501
Hemostasis, effects of DSG + EE vs EE + DRSP on, 336
Heparin-binding epidermal growth factor-like growth factor, expression in uterus in trophectoderm, effects of bromhexine on (rat), 645
Histology, endometrial, in users of Nestorone®-releasing contraceptive implant with and without endometrial bleeding, 634
Home, self-injection of monthly combined hormonal contraceptive, 53
Home monitor, used to aid in conception, psychological acceptability, 65

Homocysteine (Hcy), metabolism in women with polycystic ovary syndrome, effects of CPA + EE vs DSG + EE on, 348
Hormonal contraception,
agreement between women's and provider's risk assessment of, 501
association with STI risk, review, 154
and bone health, WHO statement, 443
COC, effective use, review, 115
combined
effects on fracture risk and BMD, review, 445
injectables, progestogen-only injectables and contraceptive implants, review, 125
monthly self-injection, 53
emergency, supply via patient group direction in UK, pharmacists' perspectives, 265
oral vs vaginal ring, acceptability and satisfaction using Quick Start initiation, 488
over-the-Internet availability of, 372
use among women with thrombogenic mutations, effect on risk of venous thromboembolism, review, 166
Hormone levels,
before and after bipolar electrocautery vs Hulka clip sterilization, 507
effects of laparoscopic tubal sterilization, 279
Hormone replacement therapy (HRT), effects on lung cancer risk in women, 331
HRT (hormone replacement therapy)
Hulka clip sterilization, vs bipolar electrocautery, hormone levels before and after, 507
Hydrogen peroxide (H_2O_2) production, of *Lactobacillus* isolated from vagina, 78
Hypertension, COC use among women with, review, 179

Implanon®,
vs Jadelle®, ovarian cysts in users of, 532
vs nonmedicated IUD, effects on growth of breast-fed infants, 368
nonpalpable rod, management and localization strategies, review, 325
unintended pregnancies with, 111
Induced abortion,
bleeding patterns after using two dosing schedules of mifepristone + misoprostol for, 415
and medical abortion, comparing patients' telephone calls after, 271
in second trimester, using mifepristone + misoprostol, 516
unintended pregnancy and contraceptive use among women who undergo, 520
using mifepristone, atypical presentation of PID after, 431
Infant growth, breast-fed, effects of nonmedicated IUD vs Implanon® on, 368
Injectable contraceptive,
DMPA vs NET-EN, preferences among South African women, 598
monthly, comparison of two regimens of Perlutan®, 249
NET-EN + estradiol valerate, bleeding patterns among adolescent users, 594
once-a-month, acceptability of testosterone undecanoate as male contraceptive in China, 548
International Vagina Dialogue Survey, women's attitudes, perceptions and knowledge about the vagina, 493
Internet, availability of hormonal contraceptives on, 372
Intrauterine device (IUD),
Actinomyces israelii in cervical smears of Singaporean women users, 352
cumulative gross discontinuation rate, 315
insertion and use, effect on risk of PID among women with STI, review, 145
nonmedicated, vs Implanon®, effects on growth of breast-fed infants, 368
uptake, knowledge and attitudes on, impact of medical education, randomized trial, 628
Intrauterine injection, of casein, effect on fetal survival (rat), 641
Intrauterine system (IUS), LNG-releasing,
effects on glucose and lipid metabolism, 528
uterine perforation in women using, 257
IUD (intrauterine device)
IUS (intrauterine system)

Jadelle®,
acceptability of Norplant transition to, 364
vs Implanon®, ovarian cysts in users of, 532

Knowledge,
about contraception among primary care medical students, 618
on IUD, impact of medical education, randomized trial, 628
of medical students, impact of different contraceptive curriculums on, 609
of women, about the vagina, International Vagina Dialogue Survey, 493
Korea, ethnic women, perceptions about contraception, 623

Lactate dehydrogenase (LDH), effect of antispermatogenic agents in Sertoli cells in vitro (rat), 102
Lactobacillus, isolated from vagina, identification, H_2O_2 production and nonoxynol-9 resistance, 78
Laparoscopy, tubal sterilization by, effects on hormonal and ovarian stromal blood supply, 279
LDH (lactate dehydrogenase)
Learning, of medical students, impact of different contraceptive curriculums on, 609

Levonorgestrel (LNG),
doses comparable to that delivered by LNG-IUS, effect on in vitro expression of zona binding sites of human spermatozoa, 97
vs DSG or norgestimate, risk of nonfatal VTE with, 566
EC, effects on ovulatory dysfunction, 107
EC pills, bleeding patterns after use of, 376
subdermal contraceptive implant (Norplant), effects on serum cholesterol, triglycerides, ALT and AST in Iranian women, 56
Levonorgestrel-releasing intrauterine device (IUD), insertion and use, effect on risk of PID among women with STI, review, 145
Levonorgestrel-releasing intrauterine system (LNG-IUS),
effects on glucose and lipid metabolism, 528
LNG doses comparable to that delivered by, effect on in vitro expression of zona binding sites of human spermatozoa, 97
new T-shaped, age factors, time of use and release rate of, 110
uterine perforation in women using, 257
Lipid metabolism, effects of LNG-IUS, 528
Lipid profile, and OGTT, of Norplant® users, long-term evaluation of, 361
LNG (levonorgestrel)
LNG-IUS (levonorgestrel-releasing intrauterine system)
Long-acting delivery systems, for contraception, international perspectives on, review, 215
Low-dose oral contraceptive (OC), for acne treatment, review, 23
Lung cancer, risk in women, effects of HRT and OC on, 331

Magnetic resonance imaging (MRI),
for localizing nonpalpable Implanon™ rod, review, 325
quantification of microbicide distribution, 82
Male contraceptive, acceptability of once-a-month injectable testosterone undecanoate in China, 548
Malformations of the fetus, and termination of twin pregnancy failure, 109
D-Mannose binding sites, of ZP, in vitro expression in human spermatozoa, effect of LNG doses comparable to that delivered by LNG-IUS, 97
Matrix metalloproteinase-3 (MMP-3), expression in endometrium, in users of Nestorone®-releasing contraceptive implant with and without endometrial bleeding, 634
Medical abortion,
early, vaginal mifepristone + misoprostol, 261
outcomes of very low dose mifepristone + vaginal misoprostol for, 525
and surgical abortion, comparing patients' telephone calls after, 271
of twin pregnancy with oral mifepristone, failure of, 109
using mifepristone, atypical presentation of PID after, 431
Medical education, impact on IUD uptake, knowledge and attitudes, randomized trial, 628
Medical residents,
for family medicine, effect of educational intervention on interest in early abortion training among, 613
in primary care, attitudes and knowledge about contraception among, 618
Medical students, impact of different contraceptive curriculums on knowledge retention and learning skills of, 609
Menstrual cycle,
after use of LNG EC pills, 376
effect of GTD + EE (Minesse®), 30
Menstruation,
desired frequency among women without menstrual-related symptoms, 537
effects of smoking, review, 562
pattern, after bipolar electrocautery of fallopian tubes for voluntary surgical contraception, 88
Mexico, short-term acceptability of PATH Woman's Condom among users in, 588
Microbicides,
2% nonoxynol-9 vs ACIDFORM, vaginal safety of, 542
clinical safety, 72
quantification of distribution with MRI, 82
Microvascular density, endometrial, in users of Nestorone®-releasing contraceptive implant with and without endometrial bleeding, 634
Mifepristone,
atypical presentation of PID after induced abortion using, 431
in failed medical abortion of twin pregnancy, 109
Mifepristone + misoprostol,
for medical abortion, outcomes of, 525
for second-trimester abortion, 516
for TOP
bleeding patterns after using two dosing schedules, 415
at more than 15 weeks' gestation in patients with previous cesarean section, 244
vaginal, in early medical abortion, 261
Migraine, vs nonmigrainous headaches, risk of stroke among COC users with, review, 189
Military, women who request for sterilization reversal, 512
Minesse®, (GTD + EE), safety and acceptability, 30
Misoprostol, buccal, adequacy and safety for cervical preparation before second-trimester TOP, 420
Misoprostol + mifepristone,
for medical abortion, outcomes of, 525
for second-trimester abortion, 516
for TOP
bleeding patterns after using two dosing schedules, 415
at more than 15 weeks' gestation in patients with previous cesarean section, 244
vaginal, in early medical abortion regimen, 261

MMP-3 (Matrix metalloproteinase-3)
Myocardial infarction, risk, association with COC use among women with hypertension, review, 179

Nestorone® + EE, vaginal ring for EC, 46
Nestorone®-releasing contraceptive implant, endometrial histology, microvascular density and MMP-3 expression in users with and without endometrial bleeding, 634
(NET-EN) (norethisterone enanthate)
Nonoxynol-9,
microbicide, vs ACIDFORM, vaginal safety of, 542
resistance of *Lactobacillus* isolated from vagina, 78
Norethisterone enanthate (NET-EN), vs DMPA, injectable, preferences among South African women, 598
Norethisterone enanthate (NET-EN) + estradiol valerate, injectable, bleeding patterns among adolescent users, 594
Norgestimate, or DSG, vs LNG, risk of nonfatal VTE with, 566
Norgestimate + EE, OC vs transdermal patch, risk of nonfatal VTE in women using, 223
Norplant®,
acceptability of transition to Jadelle, 364
effect of tranexamic acid for treatment of irregular uterine bleeding secondary to use of, 253
effects on serum cholesterol, triglycerides, ALT and AST in Iranian women, 56
long-term evaluation of lipid profile and OGTT in users of, 361
side effects, pregnancy rate and continuation rate in southern Thai women users, 356
NP (nurse practitioner)
Nurse practitioner (NP), programs in the United States, abortion education in, 408

OC (oral contraceptive)
Occupational exposure, to fenvalerate, effects on semen quality, 92
Office, self-injection of monthly combined hormonal contraceptive, 53
OGTT (oral glucose tolerance test)
Oral administration, very low dose mifepristone, plus vaginal misoprostol for medical abortion, outcomes of, 525
Oral contraceptive (OC),
coagulation tests to determine risk of thrombophlebitis among users, 4
combined
causing skin VTE in women with acquired angioedema and Factor V Leiden mutation, 311
use among women with thrombogenic mutations, effect on risk of venous thromboembolism, review, 166
conventional vs continuous use, ovarian follicular dynamics during, 235
Oral contraceptive, (*continued*)
DRSP + EE
vs DSG + EE, effects on hemostasis, 336
vs EE + GTD, effects on total body water, 344
Yasmin®, safety, acceptance and bleeding profile in an extended 126-day regimen, 34
EE + DSG vs EE + CPA, in women with polycystic ovary syndrome, effects on Hcy metabolism, 348
effects on lung cancer risk in women, 331
extended-regimen, utilizing continuous low-dose EE, safety and efficacy, 229
and fracture risk, 571
GTD + EE (Minesse®), safety and acceptability, 30
LNG vs DSG or norgestimate, risk of nonfatal VTE with, 566
over-the-Internet availability of, 372
pill, switch from DMPA, effects on BMD, 577
vs transdermal patch, containing norgestimate + EE, risk of nonfatal VTE in women using, 223
use of lower doses in acne treatment, review, 23
vs vaginal ring, acceptability and satisfaction using Quick Start initiation, 488
Oral glucose tolerance test (OGTT), and lipid profile, of Norplant® users, long-term evaluation of, 361
Osteopontin, expression in uterus in trophectoderm, effects of bromhexine on (rat), 645
Outcomes, of very low dose mifepristone + vaginal misoprostol for medical abortion, 525
Ovarian cysts, in Jadelle® vs Implanon® users, 532
Ovarian function,
after bipolar electrocautery of fallopian tubes for voluntary surgical contraception, 88
during conventional vs continuous OC use, 235
Ovarian stromal artery, blood supply, effects of laparoscopic tubal sterilization, 279
Over-the-Internet availability, of hormonal contraceptives, 372
Ovulation prevention,
effective use of COC, review, 115
effective use of combined hormonal injectables, progestogen-only injectables and contraceptive implants, review, 125
Ovulatory dysfunction,
effects of LNG EC, 107
effects of Nestorone® + EE vaginal ring, 46

PA (physician assistant)
Parental communication, as source of sexual information, relation to sexual behavior among female adolescents, 274
Parental involvement, in adolescents' abortion, ARHP editorial, 211
PATH Woman's Condom, short-term acceptability among users in Mexico, South Africa and Thailand, 588
Patient group direction, in UK, pharmacists' perspectives on supply of emergency hormonal contraception via, 265

Pelvic inflammatory disease (PID),
atypical presentation after mifepristone-induced medical abortion, 431
risk among women with STI, effect of IUD insertion and use, review, 145
Pennsylvania, EC availability at rural and urban pharmacies in, 382
Perceptions, of women, about the vagina, International Vagina Dialogue Survey, 493
Perlutan®, monthly injectable contraceptive, comparison of two regimens of, 249
Petechiae, effect of three vaginal applicators, 72
Pharmacist, DMPA administered by, 559
Pharmacy, access to EC pills, impact on contraceptive use and sexual behavior in France, 602
Physician assistant (PA), programs in the United States, abortion education in, 408
PID (pelvic inflammatory disease)
Polycystic ovary syndrome, effects of CPA + EE vs DSG + EE on Hcy metabolism in women with, 348
Population control, in wildlife, humans as models, 6
Postcoital ingestion, of aqueous extract of *Erythrina falcata* Benth, contraceptive effect (mouse), 307
Postpartum period, barriers to tubal sterilization, 404
Prangos ferulacia, abortifacient effect (rat), 554
Pregnancy,
home monitor used to aid, psychological acceptability, 65
twin, failed medical termination with mifepristone, 109
Pregnancy rate, of Norplant implantation in southern Thai women, 356
Pregnanediol, levels before and after bipolar electrocautery vs Hulka clip sterilization, 507
Premenstrual symptoms, effect of GTD + EE (Minesse®), 30
Prescribing habits, of health care providers in US regarding extended-cycle OC, 41
Primary care, attitudes and knowledge about contraception among medical residents in, 618
Product labeling, evidence-based decision making by FDA, 440
Progesterone, levels before and after bipolar electrocautery vs Hulka clip sterilization, 507
Progestogen-only contraceptive,
effects on fracture risk and BMD, review, 470
injectable, effective use, review, 125
use among women with sickle cell anemia, review, 195

Qualitative study, pharmacists' perspectives on supply of emergency hormonal contraception via patient group direction in UK, 265
Quick Start initiation, of vaginal ring vs OC, acceptability and satisfaction, 488
Quinacrine sterilization, decreased failures due to transvaginal sonographic diagnosis of septate uteri, 433

Randomized controlled trials,
on EE + DRSP
vs DGS + EE, effects on hemostasis, 336
vs EE + GTD, effects on total body water, 344
impact of medical education on IUD uptake, knowledge and attitudes, 628
Randomized crossover trials, on synthetic latex prototype vs Reality® female condom among South African women,
performance of, 386
short-term acceptability of, 394
Reality®, vs synthetic latex prototype,
performance among South African women, 386
short-term acceptability among South African women, 394
Regret, following female sterilization at young age, review, 205
Release rate, of new T-shaped LNG-IUS, 110
Reproductive health, risks in perspective, ARHP editorial, 437
Reproductive technologies, home monitor used to aid in conception, psychological acceptability, 65
Risk,
of cardiovascular events in COC users with hypertension, review, 179
of fracture
effects of combined hormonal contraception, review, 445
effects of progestogen-only contraception, review, 470
OC and, 571
of lung cancer in women, effects of HRT and OC on, 331
of nonfatal VTE with norgestimate or DSG vs LNG, 566
of PID among women with STI, effect of IUD insertion and use, review, 145
in reproductive health, ARHP editorial, 437
of stroke, among COC users with migraine vs nonmigrainous headaches, review, 189
of thrombophlebitis among OC users, determined by coagulation tests, 4
Risk assessment, of hormonal contraception, agreement between women and providers, 501
Royal College of General Practitioners' Oral Contraception Study, effects of HRT and OC on lung cancer risk in women, 331
Rural pharmacy, in Pennsylvania, EC availability at, 382

Safety,
buccal misoprostol for cervical preparation before second-trimester TOP, 420
EE + DRSP (Yasmin®) in an extended 126-day regimen, 34
FemCap™ with removal strap, 59
GTD + EE (Minesse®), 30
mifepristone + misoprostol for TOP at more than 15 weeks' gestation in patients with previous cesarean section, 244

Safety, (*continued*)
Seasonique™, 229
three vaginal applicators, 72
vaginal, of ACIDFORM vs 2% nonoxynol-9 microbicide, 542
Satisfaction, with vaginal ring vs OC using Quick Start initiation, 488
Seasonique™, safety and efficacy, 229
Second-trimester abortion,
induction using mifepristone + misoprostol, 516
safety and adequacy of buccal misoprostol for cervical preparation before, 420
Self-injection, of monthly combined hormonal contraceptive, 53
Semen quality, effects of fenvalerate exposure among occupational workers, 92
Septate uteri, decreased failures of quinacrine sterilization due to transvaginal sonographic diagnosis of, 433
Sertoli cells, effect of antispermatogenic agents on cell marker enzymes in vitro (rat), 102
Sexual behavior,
of female adolescents, relation to source of sexual information, 274
in France, impact of pharmacy access to EC pills on, 602
Sexual information, source, relation to sexual behavior among female adolescents, 274
Sexually transmitted infection (STI),
effect of IUD insertion and use on risk of PID among women with, review, 145
risk of, association with hormonal contraceptive use, review, 154
Sialomucin complex, expression in uterus in trophectoderm, effects of bromhexine on (rat), 645
Sickle cell anemia, progestogen-only contraceptive use among women with, review, 195
Side effects, of Norplant implantation in southern Thai women, 356
Singapore, *Actinomyces israelii* in cervical smears of women using IUD, 352
Skin venous thromboembolism, by COC, in women with acquired angioedema and Factor V Leiden mutation, 311
Smoking, effects on bleeding patterns, review, 562
Society of Family Planning, ARHP editorial, 557
South Africa,
short-term acceptability of PATH Woman's Condom among users in, 588
synthetic latex prototype vs Reality® female condom among women users
performance of, 386
short-term acceptability of, 394
women, preferences between injectable DMPA and NET-EN, 598
Sperm morphology, effects of fenvalerate exposure among occupational workers, 92
Sperm viability, in vitro effect of *Achyranthes aspera* and *Stephania hernandifolia* extract on human semen, 284
Spermatozoa, human, in vitro effect of LNG doses comparable to that delivered by LNG-IUS on expression of zona binding sites of, 97
Stephania hernandifolia, and *Achyranthes aspera*, extract of, in vitro effect on spermicidal viability, 284
Sterilization, nonsurgical, evaluation of single intratesticular injection of calcium chloride for (rat), 289
STI (sexually transmitted infection)
Stroke risk, among COC users,
with hypertension, review, 179
with migraine vs nonmigrainous headaches, review, 189
Surgical abortion, and medical abortion, comparing patients' telephone calls after, 271
Surgical contraception, voluntary, bipolar electrocautery of fallopian tubes for, effect on menstrual pattern and ovarian function, 88
Survival, of fetus, effect of intrauterine casein injection on (rat), 641
Synthetic latex prototype, vs Reality®,
performance among South African women, 386
short-term acceptability among South African women, 394
Systematic review,
association between hormonal contraceptive use and risk of STI, 154
COC use among women with hypertension, review, 179
combined hormonal contraception and bone health, review, 445
effect of hormonal contraceptive use on risk of venous thromboembolism among women with thrombogenic mutations, 166
effect of IUD insertion and use on risk of PID among women with STI, 145
effective use of COC, 115
effective use of combined hormonal injectables, progestogen-only injectables and contraceptive implants, 125
progestogen-only contraception and bone health, review, 470
progestogen-only contraceptive use among women with sickle-cell anemia, 195
regret following female sterilization at young age, 205
risk of stroke among COC users with migraine and nonmigrainous headaches, 189

T-shaped levonorgestrel-intrauterine system (LNG-IUS), time of use, release rate and age factors, 110
Telephone calls, of patients, after medical and surgical abortions, 271

Termination of pregnancy (TOP),
bleeding patterns after using two dosing schedules of mifepristone + misoprostol for, 415
at more than 15 weeks' gestation, in patients with previous cesarean section, 244
second-trimester, safety and adequacy of buccal misoprostol for cervical preparation before, 420
twin, failure with mifepristone, 109
Testosterone undecanoate, once-a-month injectable, acceptability as male contraceptive in China, 548
Thailand,
short-term acceptability of PATH Woman's Condom among users in, 588
southern, side effects, pregnancy rate and continuation rate of Norplant implants in women users, 356
Thrombogenic mutations, effect of hormonal contraceptive use on risk of venous thromboembolism among women with, review, 166
Thrombophlebitis, risk among OC users, determined by coagulation tests, 4
Time factors,
effective use of COC, review, 115
effective use of combined hormonal injectables, progestogen-only injectables and contraceptive implants, review, 125
Time of use, of new T-shaped LNG-IUS, 110
TOP (termination of pregnancy)
Total body water, effects of DRSP + EE vs GTD + EE on, 344
Training program, on abortion, among family medicine residents, effect of educational intervention on interest in, 613
Tranexamic acid, for treatment of irregular uterine bleeding secondary to Norplant® use, 253
Transdermal patch,
vs OC, containing norgestimate + EE, risk of nonfatal VTE in women using, 223
over-the-Internet availability of, 372
Transvaginal ultrasound, in diagnosis of septate uteri diminishes failures of quinacrine sterilization, 433
Triglycerides, total, effects of Norplant in Iranian women, 56
Trophectoderm, effects of bromhexine on glycoprotein expression in (rat), 645
Tubal anastomosis, after bilateral tubal ligation, women in a military population who request for, 512
Tubal sterilization,
bilateral, women in a military population who request for reversal of, 512
Hulka clip vs bipolar electrocautery, hormone levels before and after, 507
laparoscopic, effects on hormonal and ovarian stromal blood supply, 279
postpartum, barriers to, 404
Twin pregnancy, failed medical abortion with oral mifepristone, 109
UK (United Kingdom)
Ultrasound,
for localizing nonpalpable Implanon™ rod, review, 325
transvaginal, in diagnosis of septate uteri diminishes failures of quinacrine sterilization, 433
Unintended pregnancy,
and contraceptive use, among women who undergo induced abortion, 520
with use of Implanon, 111
United Kingdom (UK), pharmacists' perspectives on supply of emergency hormonal contraception via patient group direction in, 265
United States, abortion education in NP, PA and CNM programs in, 408
United States Food and Drug Administration (FDA), evidence-based decision making about product labeling, 440
Urban pharmacy, in Pennsylvania, EC availability at, 382
Uterine bleeding, irregular,
in DMPA users, efficacy of valdecoxib for control of, 584
secondary to Norplant® use, effect of tranexamic acid for, 253
Uterine perforation, in women using LNG-IUS, 257
Uterine secretory protein-1, expression in uterus in trophectoderm, effects of bromhexine on (rat), 645
Uterus, effects of bromhexine on glycoprotein expression in (rat), 645

Vagina,
irritation, effect of FemCap™ with removable strap, 59
Lactobacillus isolated from, identification, H_2O_2 production and nonoxynol-9 resistance, 78
safety of ACIDFORM vs 2% nonoxynol-9 microbicide, 542
women's attitudes, perceptions and knowledge about, International Vagina Dialogue Survey, 493
Vaginal administration,
of mifepristone + misoprostol in early medical abortion, 261
misoprostol, plus very low dose oral mifepristone for medical abortion, outcomes of, 525
Vaginal applicators, clinical safety, 72
Vaginal gel, MRI quantification of microbicide distribution, 82
Vaginal ring,
Nestorone® + EE for EC, 46
vs OC, acceptability and satisfaction using Quick Start initiation, 488
Valdecoxib, efficacy for controlling irregular uterine bleeding in DMPA users, 584
Venous thromboembolism (VTE),
nonfatal, risk
in women using transdermal patch vs OC containing norgestimate + EE, 223
with use of norgestimate or DSG vs LNG, 566

Venous thromboembolism (VTE), (*continued*)
risk
association with COC use among women with hypertension, review, 179
effect of hormonal contraceptive use among women with thrombogenic mutations, review, 166
skin, by COC, in women with acquired angioedema and Factor V Leiden mutation, 311
VTE (venous thromboembolism)

WHO (World Health Organization)
Wildlife, humans as models of fertility control in, 6
Women,
with acquired angioedema and Factor V Leiden mutation, skin VTE by COC, 311
attitudes, perceptions and knowledge about the vagina, International Vagina Dialogue Survey, 493
effects of HRT and OC on lung cancer risk in, 331
ethnic Korean, perceptions about contraception, 623
in a military population, who request for sterilization reversal, 512
nonfatal VTE risk in users of transdermal patch vs OC containing norgestimate + EE, 223
with polycystic ovary syndrome, effects of CPA + EE vs DSG + EE on Hcy metabolism in, 348
vs providers, agreement on risk assessment of hormonal contraception, 501
Women, (*continued*)
Singaporean, *Actinomyces israelii* in cervical smears IUD users, 352
South African
performance of synthetic latex prototype vs Reality® female condom among, 386
preferences between injectable DMPA and NET-EN, 598
short-term acceptability of synthetic latex prototype vs Reality® female condom among, 394
southern Thai, side effects, pregnancy rate and continuation rate of Norplant implants in, 356
using LNG-IUS, uterine perforation in, 257
who undergo induced abortion, contraceptive use and unintended pregnancy among, 520
without menstrual-related symptoms, desired menstrual frequency among, 537
World Health Organization (WHO), statement on hormonal contraception and bone health, 443

Yasmin®, EE + DRSP, safety, acceptance and bleeding profile in an extended 126-day regimen, 34

Zona pellucida (ZP), in vitro expression of D-mannose binding sites of, effect of LNG doses comparable to that delivered by LNG-IUS in human spermatozoa, 97
ZP (zona pellucida)